Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Tekchandani, Chitra
- Tamsulosin for the Treatment of Voiding Dysfunction in Women – A Review
Abstract Views :227 |
PDF Views:0
Authors
Affiliations
1 Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, IN
1 Aristo Pharmaceuticals Ltd, 23-A Shah Industrial Estate, Veera Desai Road, Andheri (West), Mumbai, IN
Source
The Indian Practitioner, Vol 71, No 10 (2018), Pagination: 34-38Abstract
Lower urinary tract symptoms (LUTS) have high prevalence worldwide in the aging population including both, men and women and with the advancing age, the incidence of LUTS continues to increase. Interference of the symptoms with the daily activities has a negative impact on the quality of life of many individuals. Apart from watchful waiting and surgery, medical therapies have shown to provide significant control of LUTS. α1- adrenergic receptor blockers are used as first-line therapy for men to alleviate Benign Prostatic Hyperplasia (BPH) induced urinary symptoms. Similar underlying etiology of LUTS in men and women proposes the utility of α1-adrenergic receptor blockers for female lower urinary tract symptoms (FLUTS). Tamsulosin, the highly uroselective α1-adrenergic receptor blocker, has steadily borne positive results in symptomatic management of FLUTS. Improvement in quality of life has been a vital criteria in the assessment of the efficacy of Tamsulosin. All the reviewed studies substantiate the safety and tolerability of Tamsulosin. Numerous clinical trials of Tamsulosin in women suggest the suitability of Tamsulosin as an appropriate therapeutic option for management of female LUTS.Keywords
Tamsulosin, Luts/ Fluts, α1-adrenergic Receptors, Bladder, Urethra.
References
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P.
- Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology 2006; 50(6):1306-15
- Meyer LE, Brown JN. Tamsulosin for voiding dysfunction in women. International urology and nephrology 2012;44(6):1649-56.
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology. 2002;187(1):116-26.
- Goodwin J.(2012) Incontinence Affects Young Childless Women, Too. HealthDay®https://consumer.healthday.com/senior-citizen-information-31/age-health-news-7/incontinenceaffects-young-childless-women-too-666623.html Accessed 25 August 2016.
- Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU international. 2009;104(3):352-60.
- Booth AM. Physiology of the urinary bladder and urethra. Annals of internal medicine.1980. 92(2_Part_2):312-5.
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology. 2002;187(1):116-26.
- Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, WeinAJ.How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU international.2001;87(9):760-6.
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology. 2006;50(6):1306-15.
- Wagg AS, Cardozo L, Chapple C, De Ridder D, Kelleher C, Kirby M, Milsom I, Vierhout M. Overactive bladder syndrome in older people. BJU international .2007;99(3):502-9.
- Patel R, Nitti VW.Bladder outlet obstruction in women: prevalence, recognition, and management. Current urology reports.2001;2(5):379-87.
- Andersson, K. E., &Gratzke, C. Pharmacology of the lower urinary tract. Textbook of the neurogenic bladder 2008; 2:81-100.
- Schwinn DA. Novel role for α1‐adrenergic receptor subtypes in lower urinary tract symptoms. BJU international.2000; 86(s2):11-22.
- Price D. Potential mechanisms of action of superselective α1adrenoceptor antagonists.European urology .2001;40(Suppl. 4):5-11.
- Urinary incontinence: The management of urinary incontinence in women; NICE Clinical Guideline (2013), Royal College of Obstetricians and Gynecologists. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/themanagementof-urinary-incontinence-in-women-nice-clinicalguideline-171/ Accessed 6 May 2016
- Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non‐drug active therapies for non‐neurogenic overactive bladder syndrome in adults.Cochrane Database of Systematic Reviews.2012;Issue 12. Art. No.: CD003193.
- Mirabegron (Betmiga): risk of severe hypertension and associated cerebrovascular and cardiac events; Drug Safety Update, Medicines and Healthcare products Regulatory Agency (MHRA). (2015). https://www.gov.uk/drug-safetyupdate/mirabegron-betmiga-risk-of-severe-hypertensionand-associated-cerebrovascular-and-cardiac-events Accessed 31 May 2016
- Boyd K, Hilas O. α-Adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. Annals of Pharmacotherapy.2014;48(6):711-22.
- Michel MC, Grübbel B, Taguchi K, Verfürth F, Otto T, Kröpfl D. Drugs for treatment of benign prostatic hyperplasia: Affinity comparison at cloned α1‐adrenoceptor subtypes and in human prostate. Journal of autonomic pharmacology. 1996;16(1):21-8.
- Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. European Journal of Pharmacology: Molecular Pharmacology.1995;288(2):201-7.
- Taguchi K, Schäfers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. British journal of clinical pharmacology.1998;45(1):49-55.
- Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia.Reviews in urology. 2007;9(4):181.
- Reitz A, Haferkamp A, Kyburz T, Knapp PA, Wefer B, Schurch B. The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. European urology. 2004;46(2):235-40.
- Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian Journal of Surgery .2007;30(2):131-7.
- Lee KS, Han DH, Lee YS, Choo MS, Yoo TK, Park HJ, Yoon H, Jeong H, Lee SJ, Kim H, Park WH. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. Journal of Korean medical science .2010; 25(1):117-22.
- Kakizaki H, Ameda K, Kobayashi S, Tanaka H, Shibata T, Koyanagi T. Urodynamic effects of α1‐blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. International journal of urology. 2003;10(11):576-81.
- Lee S, Lee W, Lee S, Kim H, Park C. The effect oftamsulosin in female patients with lower urinary tractsymptoms and predictive factors for therapeutic outcome:multicenter, prospective study. IntUrogynecol J.2011;22(suppl 3):S1781.
- Pischedda A, Pirozzi Farina F, Madonia M, Cimino S, MorgiaG.Use of α1-blockers in female functional bladder neck obstruction. Urologia internationalis.2005;74(3):256-61.
- Ryu S, Kim S, Hwang E, Im C, Oh K, Jung S et al.The role of alpha 1(A) adrenoreceptor antagonist tamsulosinfor the treatment of patients with lower urinary tractsymptoms in women: the effect of nocturia and sleep quality. Urology.2010; 76(suppl 3A):S61.
- Hajebrahimi S, Asrbadr YA, Azaripour A, Sadeghi-Bazargani H. Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty: a randomized clinical trial. International journal of general medicine. 2011;4:35.
- Costantini E, Lazzeri M, Bini V, Zucchi A, Fioretti F, Frumenzio E, Porena M. Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urologia internationalis.2009;83(3):311-5.
- Kim SO, Hwang EC, Oh KJ, Kwon D, Park K, Ryu SB. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s. International urogynecology journal.2011;22(10):1287-91.
- Neĭmark, AI, Razdorskaia, MV, Kondrat’eva, I., &Muzalevskaia, NI . [Correction of urodynamic disorders in women with obstructive urination]. Urologiia (Moscow, Russia: 1999), 2012;(5), 34-37.
- COVID-19 Treatment:Current and Emerging Options
Abstract Views :206 |
PDF Views:0
Authors
Affiliations
1 Aristo Pharmaceuticals Private Limited, Mumbai, IN
1 Aristo Pharmaceuticals Private Limited, Mumbai, IN
Source
The Indian Practitioner, Vol 73, No 6 (2020), Pagination: 37-41Abstract
Coronavirus disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has posed a clinical threat to the global population. Its resemblance to SARS-CoV along with several other bat coronaviruses have been established through genome sequencing- related studies. The disease spreads by human-to-human transmission via droplets or direct contact and presents flu-like symptoms. It can have poor prognosis in high-risk individuals having co-morbid conditions. Though currently, no proven effective therapies for SARS-CoV-2 exist, many therapeutic agents are being repurposed to treat patients with COVID-19. The key aspect determining the prognosis of COVID-19 patients is the early accurate diagnosis followed by the management of acute respiratory failure and hemodynamic instability in moderate-severe cases. COVID-19 presents an unparalleled chal-lenge to identify potential therapeutic agents for prophylaxis and treatment. There is an explicit and urgent need to explore all the possible prophylactic and therapeutic strategies to curb the spread of SARS-CoV-2. A large number of clinical trials have been launched to investigate potential therapies for COVID-19 and to provide the clinicians ac-curate evidence regarding effective medical treatments for this infection. The current review closely examines the drugs that are being explored and also those drugs which have a potential for consideration. Though the therapeutic options have not undergone extensive pre-clinical and clinical testing, each has a known merit and identified mecha-nism against viral infection. The review is based on currently available information and as new evidence emerges, reappraisal of therapies is anticipated.Keywords
COVID-19, Management, SARS-CoV-2, Potential Therapies, Evidence.References
- Katulanda P, Dissanayake H A, Ranathunga I, Ratnasamy V et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia (2020). https://doi.org/10.1007/s00125-020-05164-x
- Ky B, Mann DL. COVID-19 Clinical Trials A Primer for the Cardiovascular and Cardio-Oncology Communities. 2020; 5(5): 501 – 17
- Lundstrom K. Coronavirus Pandemic—Therapy and Vaccines. Biomedicines 2020; 8(109): 1-25.
- Sanders JM, Monogue LM, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review. JAMA. 2020; 323(18):1824-1836.
- Chatterjee P, Anand T, Singh KJ, Rasaily R et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control in-vestigation in the time of COVID-19. Indian J Med Res[Epub ahead of print] [cited 2020 Jun 5].
- Das S, Bhowmick S, Tiwari S, Sen S. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Clin Drug Investig (2020). https://doi.org/10.1007/s40261-020-00927-1
- Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes New Infect. 2020; 35: 100684.
- Pizzorno A, Padey B, Julien T, Trouillet-Assant S. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. https://doi.org/10.1101/2020.03.31.017889.
- Beigel JH, Tomashek K.M, Dodd L.E, Mehta AK. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med DOI: 10.1056/NEJMoa2007764.
- Wang Y, Zhang D, Du G, Du R. Remdesivir in adults with se-vere COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial. Lancet 2020; 395: 1569–78.
- Wu Renyi, Wang L, Kuo HCD, Shannar A. et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep. 2020May 11; 1-15.
- Chen C, Huang J, Cheng Z, Wu J. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. 2020; DOI: 10.1101/2020.03.17.20037432.
- Cai Q, Yang M, Liu D, Chen J. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering, https://doi.org/10.1016/j.eng.2020.03.007.
- Simsek Yavuz, Unal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020; 50(3): 611–619.
- Retrieved from https://www.who.int/blueprint/priority-diseases/key action/Table_of_therapeutics_Appendix_17022020.pdf? ua=1.
- Caly L, Druce JD, Catton MG, Jans DA et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020Jun; 178: 104787.
- Retrieved from https://www.trialsitenews.com/ivermec-tin-usage-accelerates-while-the-need-for-data-is-real-how-about-an-ivermectin-registry/ on 31 May 2020.
- Sharun K, Dhama K, Patel K, Pathak M. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob (2020) 19:23.
- Dorward J, Gbinigie K. Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19. https://www.cebm.net/cov-id-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/
- Li L, Li R, Wu Z, Yang X. Therapeutic strategies for critically ill patients with COVID-19. Ann. Intensive Care (2020) 10:45.
- Cao B, Wang Y, Wen D, Liu W et al. A Trial of Lopinavir– Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382:1787-1799.
- Dalerba P, Levin B, Thompson JL. A Trial of Lopinavir– Ritonavir in Covid-19. N Engl J Med382; 21.
- Khalili JS, Zhu H, Mak NSA, Yan Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation con-cerning COVID-19. J Med Virol. 2020; 1–7.
- Ríos DG, VA, Agudelo López, Ramírez-Malule H. Repurposing antivirals as potential treatments for SARS-CoV-2: From SARS to COVID-19. Journal of Applied Pharmaceutical Science Vol.2020; 10(05):001-009.
- Hung IFN, Lung KC, Tso EYK, Liu R et al. Triple combination of interferon beta-1b, lopinavirBritonavir, nd ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trials.Lancet 2020; 395: 1695–704.
- Li H, Liu SM, Yu XH, Tang SL et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020May; 55(5): 105951.
- Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Critical Care (2020);24(91):1-2.
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis. J Infect Dis 2015Jan 1; 211(1):80-90.
- Zeng QL, Yu ZJ, Gou JJ, Li GM. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. J Infect Dis. 2020:1-16.
- Luo P, Liu Yi, Qiu L, Liu X. Tocilizumab treatment in COVID-19: A single center experience. Tocilizumab treat-ment in COVID-19: A single center experience.J Med Virol. 2020; 1–5.
- Le TT, Andreadakis, Z, Kumar A, Roman GR. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020; 19: 305-306.
- Retrieved from http://www.pharmabiz.com/NewsDetails.aspx?aid=126573&sid=1 on June 5, 2020.
- Derbyshire E, Delange J. bmjnph 2020;0:1–6. doi:10.1136/bmjnph-2020-000071
- R. Derwand, M. Scholz. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19? Medical Hypotheses 142 (2020)109815.
- COVID-19: Impact on Mental Health
Abstract Views :179 |
PDF Views:1
Authors
Affiliations
1 President - Medical and Regulatory Affairs, Aristo Pharmaceuticals Private Limited, Mumbai-400053, IN
2 Dy. General Manager – Medical, Aristo Pharmaceuticals Private Limited, Mumbai, IN
3 Asst. Manager – Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, IN
1 President - Medical and Regulatory Affairs, Aristo Pharmaceuticals Private Limited, Mumbai-400053, IN
2 Dy. General Manager – Medical, Aristo Pharmaceuticals Private Limited, Mumbai, IN
3 Asst. Manager – Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, IN
Source
The Indian Practitioner, Vol 74, No 2 (2021), Pagination: 17-22Abstract
The outbreak of the novel coronavirus (COVID-19) which was first detected in Wuhan, China in December 2019 has created havoc worldwide. It progressed to the status of a pandemic in March 2020 with countries across the various continents adversely affected.
This coronavirus crisis has not only affected the health, safety & well-being but has also significant negative impact on the mental health. Moreover, stigma of the disease, uncertain prognoses, imposition of unfamiliar preventive measures, large and growing economic burden, and information incessant on media platforms are among some of the major stressors that has undoubtedly contributed to widespread emotional distress. Though this coronavirus crisis has affected the mental health of almost everyone in the world, there are certain groups of people who may be more vulnerable to mental health illness than the rest of the general public. In particular, people who contract the disease, those at heightened risk for it (including the healthcare workers, elderly, people with compromised immune function, and family members/close contacts of COVID-19 patients) and people with pre-existing medical, psychiatric illness are at increased risk for adverse mental health outcomes. This review focusses on impact of COVID-19 on mental health of various population and explores various strategies to tackle these health concerns.
Keywords
COVID-19, Mental Health, Neuropsychiatric Symptoms.References
- World Health Organization [Internet]. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. [Accessed on February 12, 2020]. Available from: http://www.who.int/dg/speeches/detail/who-director-general-sremarks at-the-media-briefing-on-2019-ncov-on-11-february-2020.
- National Institute of Mental Health & Neurosciences. Department of Psychiatry. Mental Health in the times of COVID-19 Pandemic Guidelines for General Medical and Specialised Mental Health Care Settings. Bengaluru; 2020.
- Kar SK, Yasir Arafat SM, Kabir R, Sharma P, Saxena SK. Coping with Mental Health Challenges During COVID-19. Coronavirus Disease 2019 (COVID-19). 2020 Apr 30:199–213.
- Benson NM, Öngür D, Hsu J. COVID-19 testing and patients in mental health facilities. Lancet Psychiatry. 2020;7:476.
- Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7:e21.
- Zhu Y, Chen L, Ji H, et al. The Risk and Prevention of Novel Coronavirus Pneumonia Infections Among Inpatients in Psychiatric Hospitals. Neurosci Bull. 2020;36:299.
- Shechter A, Diaz F, Moise N, et al. Psychological distress, coping behaviors, and preferences for support among New York healthcare workers during the COVID-19 pandemic. Gen Hosp Psychiatry. 2020;66:1.
- Lai J, Ma S, Wang Y, et al. Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Netw Open 2020;3:e203976.
- Xiang Y, Jin Y, Cheung T. Joint International Collaboration to Combat Mental Health Challenges During the Coronavirus Disease 2019 Pandemic. JAMA Psychiatry. 2020;77(10):989– 990.
- Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611.
- Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, Ho RC. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020 Mar 6;17(5):1729.
- Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. 2020;296(2):E119-E120.
- Bergquist S, Otten T, Sarich N. COVID-19 pandemic in the United States. Health Policy Technol. 2020;9(4):623-638.
- Kiser SB, Bernacki RE. When the Dust Settles: Preventing a Mental Health Crisis in COVID-19 Clinicians. Ann Intern Med. 2020 Oct 6;173(7):578-579.
- Abbasi J. Prioritizing Physician Mental Health as COVID-19 Marches On. JAMA. 2020 Jun 9;323(22):2235-2236.
- Dzau VJ, Kirch D, Nasca T. Preventing a Parallel Pandemic A National Strategy to Protect Clinicians’ Well-Being. N Engl J Med. 2020 Aug 6;383(6):513-515.
- Kisely S, Warren N, McMahon L, Dalais C, Henry I, Siskind D. Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis. BMJ. 2020 May 5;369:m1642.
- Li W, Yang Y, Liu ZH, Zhao YJ, Zhang Q, Zhang L, Cheung T, Xiang YT. Progression of Mental Health Services during the COVID-19 Outbreak in China. Int J Biol Sci. 2020 Mar 15;16(10):1732-1738.
- Rossi R, Socci V, Pacitti F, et al. Mental Health Outcomes Among Frontline and Second- Line Health Care Workers During the Coronavirus Disease 2019 (COVID-19) Pandemic in Italy. JAMA Netw Open. 2020; 3:e2010185.
- Potloc [Internet]. Canadian Public Health Association. Study: Perception of Canadian health workers around the COVID-19 outbreak. 2020 April 16 [Accessed on July 05, 2020]. Available from: https://potloc.com/blog/en/potlocstudy canadian-health-workers-insights-front-lines-covid-19-pandemic/ .
- Tan BYQ, Chew NWS, Lee GKH, Jing M, Goh Y, Yeo LLL, Zhang K, Chin HK, Ahmad A, Khan FA, Shanmugam GN, Chan BPL, Sunny S, Chandra B, Ong JJY, Paliwal PR, Wong LYH, Sagayanathan R, Chen JT, Ng AYY, Teoh HL, Ho CS, Ho RC, Sharma VK. Psychological Impact of the COVID-19 Pandemic on Health Care Workers in Singapore. Ann Intern Med. 2020 Aug 18;173(4):317-320.
- Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS, Ho RC. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020 Mar 6;17(5):1729.
- Zhou J, Liu L, Xue P, Yang X, Tang X. Mental Health Response to the COVID-19 Outbreak in China. Am J Psychiatry. 2020 Jul 1;177(7):574-575.
- Costa M, Pavlo A, Reis G, Ponte K, Davidson L. COVID-19 Concerns Among Persons With Mental Illness. Psychiatr Serv. 2020 Nov 1;71(11):1188-1190.
- Tang W, Hu T, Hu B, Jin C, Wang G, Xie C, Chen S, Xu J. Prevalence and correlates of PTSD and depressive symptoms one month after the outbreak of the COVID-19 epidemic in a sample of home-quarantined Chinese university students. J Affect Disord. 2020 Sep 1;274:1-7.
- Tian F, Li H, Tian S, Yang J, Shao J, Tian C. Psychological symptoms of ordinary Chinese citizens based on SCL-90 during the level I emergency response to COVID-19. Psychiatry Res. 2020 Jun;288:112992.
- McGinty EE, Presskreischer R, Han H, Barry CL. Psychological Distress and Loneliness Reported by US Adults in 2018 and April 2020. JAMA. 2020 Jul 7;324(1):93-94.
- Grover S, Sahoo S, Mehra A, Avasthi A, Tripathi A, Subramanyan A, Pattojoshi A, Rao GP, Saha G, Mishra KK, Chakraborty K, Rao NP, Vaishnav M, Singh OP, Dalal PK, Chadda RK, Gupta R, Gautam S, Sarkar S, Sathyanarayana Rao TS, Kumar V, Janardran Reddy YC. Psychological impact of COVID-19 lockdown: An online survey from India. Indian J Psychiatry. 2020 Jul-Aug;62(4):354-362.
- Banerjee D, Viswanath B. Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses. Asian J Psychiatr. 2020 Dec;54:102350.
- Roy A, Singh AK, Mishra S, Chinnadurai A, Mitra A, Bakshi O. Mental health implications of COVID-19 pandemic and its response in India. Int J Soc Psychiatry. 2020 Sep 1:20764020950769.